Trial reportPharmacoEconomics2006
Encouraging smokers to quit: the cost effectiveness of reimbursing the costs of smoking cessation treatment.
Trial report in PharmacoEconomics, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Breaking the habit: a systematic review of the cost-effectiveness of non-pharmacological and combined interventions for smoking cessation in Europe.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Pooled it
- Healthcare financing systems for increasing the use of tobacco dependence treatment.The Cochrane database of systematic reviews · 2017Pooled it
- Cost-effectiveness and cost-utility of Internet-based computer tailoring for smoking cessation.Journal of medical Internet research · 2013Trial
- Estimating the Cost of Delivering Tobacco Cessation Intervention Package at Noncommunicable Disease Clinics in Two Districts of North India.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2023Article
- Cost Analysis of Community-Based Smoking Cessation Services in Vietnam: A Cluster-Randomized Trial.Health services insights · 2021Article
- The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence.Tobacco use insights · 2015Review
- Review
- Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.PharmacoEconomics · 2010Review
- Analysis of cost effectiveness of screening Danish men aged 65 for abdominal aortic aneurysm.BMJ (Clinical research ed.) · 2009Article
- U.S. military mental health care utilization and attrition prior to the wars in Iraq and Afghanistan.Social psychiatry and psychiatric epidemiology · 2009Article
- Is population screening for abdominal aortic aneurysm cost-effective?BMC cardiovascular disorders · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSmoking cessation should be encouraged in order to increase life expectancy and reduce smoking-related healthcare costs. Results of a randomised trial suggested that reimbursing the costs of smoking cessation treatment (SCT) may lead to an increased use of SCT and an increased number of quitters versus no reimbursement.
objectiveTo assess whether reimbursement for SCT is a cost-effective intervention (from the Dutch societal perspective), we calculated the incremental costs per quitter and extrapolated this outcome to incremental costs per QALY saved versus no reimbursement.
methodsIn the reimbursement trial, 1266 Dutch smokers were randomly assigned to the intervention or control group using a randomised double consent design. Reimbursement for SCT was offered to the intervention group for a period of 6 months. No reimbursement was offered to the control group. Prolonged abstinence from smoking was determined 6 months after the end of the reimbursement period. The QALYs gained from quitting were calculated until 80 years of age using data from the US. Costs (year 2002 values) were determined from the societal perspective during the reimbursement period (May-November 2002). Benefits were discounted at 4% per annum. The uncertainty of the incremental cost-effectiveness ratios was estimated using non-parametric bootstrapping.
resultsEighteen participants in the control group (2.8%) and 35 participants in the intervention group (5.5%) successfully quit smoking. The costs per participant were 291 euro and 322 euro, respectively. If society is willing to pay 1000 euro or 10,000 euro for an additional 12-month quitter, the probability that reimbursement for SCT would be cost effective was 50% or 95%, respectively. If society is willing to pay 18,000 euro for a QALY, the probability that reimbursement for SCT would be cost effective was 95%. However, the external validity of the extrapolation from quitters to QALYs is uncertain and several assumptions had to be made.
conclusionReimbursement for SCT may be cost effective if Dutch society is willing to pay 10,000 euro for an additional quitter or 18,000 euro for a QALY.
Indexed as
Identifiers
16706571What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.